Pharmacological Management of Obesity in Patients with Type 2 Diabetes: An Update
10.7570/kjo.2016.25.3.121
- Author:
Eun Ju LEE
1
;
Tae Nyun KIM
Author Information
1. Department of Internal Medicine, Cardiovascular and Metabolic Disease Center, Inje University, Busan, Korea. kimtn031@gmail.com
- Publication Type:Review
- Keywords:
Obesity;
Type 2 diabetes;
Anti-obesity drugs,;
SGLT2 inhibitors;
GLP-1 receptor agonists
- MeSH:
Cardiovascular Diseases;
Drug Therapy;
Health Behavior;
Humans;
Life Style;
Obesity;
Overweight;
Weight Loss
- From:Korean Journal of Obesity
2016;25(3):121-128
- CountryRepublic of Korea
- Language:English
-
Abstract:
Type 2 diabetes is closely linked with obesity. Obesity is associated with risk of both development and progression of type 2 diabetes, as well as cardiovascular disease. Although lifestyle modifications aimed at prompting weight reduction are cornerstone therapies in managing type 2 diabetes, weight reduction remains challenging for overweight and obese patients with type 2 diabetes. A shift in the approach to weight management in patients with type 2 diabetes is clearly needed. Pharmacotherapy should be considered as a realistic treatment option for patients with type 2 diabetes who cannot lose weight with health behavior modification alone. This review is focused on current pharmacotherapies for obesity to support the glycemic and weight loss goals of obese people with type 2 diabetes.
